DEA files formal public comment opposing any NDAA 2027 ibogaine scheduling waiver language, citing diversion risk and insufficient Schedule I exception precedent.

The DEA (U.S. Drug Enforcement Administration) will file an official public objection if Congress tries to carve out ibogaine as a legal exception to Schedule I drug rules in the 2027 defense bill. This matters because ibogaine is a Schedule I drug with abuse risk, and the DEA has a legal duty to oppose scheduling exemptions. The agency opposed similar exemptions for kratom and will likely do the same here.

DEA has statutory obligation to comment on scheduling-adjacent legislative proposals affecting Schedule I substances. The agency opposed the kratom scheduling exemption and has consistently resisted carve-outs. No credible counterargument exists for DEA staying silent on a Schedule I waiver embedded in defense legislation. Resolution is public and documentable via Federal Register or congressional record.